IgA Nephropathy (IgAN) Market Trends, Growth Drivers, and Forecast (2034)


IgA nephropathy (IgAN), also known as Berger’s disease, is a chronic kidney disease characterized by the deposition of immunoglobulin A (IgA) in the glomeruli, leading to progressive kidney damage. It often presents with hematuria, proteinuria, and sometimes hypertension, ultimately increasing the risk of end-stage renal disease (ESRD). Despite its prevalence, effective targeted therapies for IgAN remain limited, driving research and development in this domain.

IgA nephropathy Epidemiology Overview

Globally, IgAN is a leading cause of primary glomerulonephritis, with significant regional variability in its incidence and prevalence. In the seven major markets (7MM), including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, the prevalence of IgAN is estimated to be approximately 5 cases per 100,000 population in 2023. Japan reports the highest prevalence due to increased screening and diagnosis. In contrast, lower detection rates in Western countries result in fewer reported cases, though the actual burden may be underestimated.

Key IgA nephropathy Companies In The Market Landscape:

The key IgA nephropathy companies in the market include - Calliditas Therapeutics AB, Travere Therapeutics, Inc, Omeros, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., and others.

IgA nephropathy Market Insights

The IgAN market is poised for growth with increasing disease awareness and the advancement of targeted therapies. Current management options include angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) for supportive care, while emerging therapies like targeted immunosuppressants and complement inhibitors are expected to revolutionize treatment paradigms.

IgA nephropathy Market Forecast and Growth Drivers

The IgAN market is projected to grow at a significant compound annual growth rate (CAGR) from 2023 to 2034, driven by the anticipated approval and uptake of novel therapies. These include drugs targeting the complement pathway, B-cell modulation, and endothelin receptor antagonists. With multiple late-stage clinical trials demonstrating promise, the competitive landscape is expected to expand considerably.

Conclusion:

By 2034, the IgAN market size across the 7MM is forecasted to surpass USD 4 billion. This growth reflects increasing investment in drug development, heightened disease awareness, and improved diagnostic techniques. The pipeline therapies are poised to address significant unmet needs, offering hope to patients and shaping the future of IgAN treatment.

Latest Reports Offered By DelveInsight:

Latest Blogs Offered By DelveInight:

Comments

Post a Comment

Popular posts from this blog

The Fight for Market Supremacy: OPDIVO vs. KEYTRUDA in Japan’s Cancer Treatment

Image
  Analyzing OPDIVO’s Pre-2022 Sales Decline and KEYTRUDA’s Market Ascendancy Before 2022, OPDIVO, developed by Bristol-Myers Squibb (BMS), faced a significant sales decline in Japan’s PD-1 inhibitor market. Despite its initial success, the PD-1 and PD-L1 inhibitors faced challenges from new competitors and evolving market dynamics. One key competitor was Merck's KEYTRUDA, which steadily gained market share due to its broader range of approved indications and successful clinical trial outcomes. KEYTRUDA’s market ascendancy was marked by its approval for various cancers, including melanoma, non-small cell lung cancer, and urothelial carcinoma, among others, making it a versatile choice for oncologists. How OPDIVO Outpaced KEYTRUDA in Japan’s Pharmaceutical Market In 2022, OPDIVO made a remarkable comeback, outpacing KEYTRUDA in Japan’s pharmaceutical market. This resurgence was driven by several strategic moves by BMS. The company expanded OPDIVO’s indications, securing approvals fo...
Read more

Next-generation Nephrotic Syndrome Treatments: A Glimpse into the Future

Image
Nephrotic syndrome , a condition characterized by the presence of protein in the urine, swelling, low protein levels in the blood, and high cholesterol levels, poses significant challenges for patients and healthcare providers alike. While traditional approaches such as steroids and immunosuppressants have been the mainstay of treatment, emerging therapies offer new hope for individuals battling this debilitating condition. Let's delve into the landscape of nephrotic syndrome treatment, exploring both the current approaches and the promising pipeline therapies on the horizon. Traditional Approaches for Nephrotic Syndrome Treatment: Steroids and Immunosuppressants Historically, steroids and immunosuppressants have been the cornerstone of nephrotic syndrome treatment . These medications help reduce inflammation and suppress the immune system's abnormal response, thereby alleviating symptoms and slowing disease progression. However, their efficacy can vary, and long-term use may b...
Read more

FDA Approval Marks New Hope: Eli Lilly’s Donanemab for Alzheimer’s Disease

Image
  The Birth of a Breakthrough Eli Lilly’s groundbreaking drug, Donanemab, has recently received FDA approval, marking a significant milestone in Alzheimer’s disease treatment . This innovative therapy, designed to target and reduce amyloid plaques in the brain, offers new hope for patients battling this debilitating condition. Donanemab’s approval comes at a pivotal moment, as it represents a major advancement in the Alzheimer’s disease pipeline, promising improved outcomes for those affected. Navigating Regulatory Waters The journey of Donanemab through the regulatory landscape was complex, characterized by rigorous scrutiny and extensive clinical trials. Eli Lilly’s success in obtaining FDA approval highlights the drug’s potential to revolutionize Alzheimer’s disease therapies . This regulatory endorsement not only underscores the efficacy and safety of Donanemab but also sets a new standard for the evaluation of future treatments. Donanemab: Cost and Coverage As with many groun...
Read more